An article published by the Journal of the American Medical Association highlights recent updates made to the CONSORT ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses how real-world data and real-world evidence ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...

Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior ...

Imagine what we could do if we could take that time and replace it with a single login to a centralized, one stop shop system ...

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses a recent study he led on the validity of using ...

In the Phase Ib Beamion LUNG-1 clinical trial, zongertinib, an investigational irreversible tyrosine kinase inhibitor, ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...